Paulo Henrique Guilherme Borges, Barbara Gregio, Helena Tiemi Suzukawa, Gislaine Silva-Rodrigues, Emanuella de Castro Andreassa, Isabela Madeira de Castro, Guilherme Bartolomeu-Gonçalves, Emerson José Venancio, Phileno Pinge-Filho, Viviane Monteiro Góes, Celso Vataru Nakamura, Eliandro Reis Tavares, Tatiana de Arruda Campos Brasil de Souza, Sueli Fumie Yamada-Ogatta, Lucy Megumi Yamauchi
{"title":"Strategy for the Construction of SARS-CoV-2 S and N Recombinant Proteins and Their Immunogenicity Evaluation.","authors":"Paulo Henrique Guilherme Borges, Barbara Gregio, Helena Tiemi Suzukawa, Gislaine Silva-Rodrigues, Emanuella de Castro Andreassa, Isabela Madeira de Castro, Guilherme Bartolomeu-Gonçalves, Emerson José Venancio, Phileno Pinge-Filho, Viviane Monteiro Góes, Celso Vataru Nakamura, Eliandro Reis Tavares, Tatiana de Arruda Campos Brasil de Souza, Sueli Fumie Yamada-Ogatta, Lucy Megumi Yamauchi","doi":"10.3390/biotech14020038","DOIUrl":null,"url":null,"abstract":"<p><p>This study reports the construction, expression, and purification of synthetic SARS-CoV-2 spike (S) and nucleoprotein (N) containing immunodominant epitopes. The pET28aS_epit construct included epitopes 287-317, 402, 507, 524-598, and 601-640, while the pET28aN_epit construct included residues 42-62, 153-172, and 355-401. Commercial sequences of both proteins were used as controls. The four constructs were expressed using the <i>Escherichia coli</i> BL21(DE3) star strain at 37 °C. The results show that the S protein constructs were insoluble, unlike the N protein constructs. Both recombinant proteins induced immune responses in mice and were recognized by antibodies present in sera from COVID-19-positive and/or SARS-CoV-2-vaccinated humans. No significant differences in immune recognition were observed between our constructs and the commercially available proteins. In conclusion, S_epit and N_epit could be promising starting points for the development of new strategies based on immunological reactions for the control of SARS-CoV-2 infections.</p>","PeriodicalId":34490,"journal":{"name":"BioTech","volume":"14 2","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191430/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BioTech","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/biotech14020038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This study reports the construction, expression, and purification of synthetic SARS-CoV-2 spike (S) and nucleoprotein (N) containing immunodominant epitopes. The pET28aS_epit construct included epitopes 287-317, 402, 507, 524-598, and 601-640, while the pET28aN_epit construct included residues 42-62, 153-172, and 355-401. Commercial sequences of both proteins were used as controls. The four constructs were expressed using the Escherichia coli BL21(DE3) star strain at 37 °C. The results show that the S protein constructs were insoluble, unlike the N protein constructs. Both recombinant proteins induced immune responses in mice and were recognized by antibodies present in sera from COVID-19-positive and/or SARS-CoV-2-vaccinated humans. No significant differences in immune recognition were observed between our constructs and the commercially available proteins. In conclusion, S_epit and N_epit could be promising starting points for the development of new strategies based on immunological reactions for the control of SARS-CoV-2 infections.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
